Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

Viking Therapeutics advances its dual GLP-1/GIP obesity drug into Phase 3 trials, entering a $100 billion weight loss market. Applied Digital's $7 billion CoreWeave partnership transforms it into an ...

RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older ...

Positive results from both Phase 3 trials (VEGA-2 and VEGA-3) support future FDA application for Phentolamine Ophthalmic Solution 0.75%, potentially leading to market access and revenue generation.

Blue Owl, Chirisa Technology Parks and PowerHouse Data Centers Announce Next Phase of $5 Billion Joint Venture Development Partnership By Chirisa Piscataway Inc. May 28, 2025 Updated May 28, 2025 ...